FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer

HER2-mutant non-small cell lung cancer has long been an underserved niche in thoracic oncology. While HER2 amplification and overexpression have been targeted in breast and gastric cancers for decades, activating mutations in the HER2 tyrosine kinase domain in NSCLC have only recently gained regulatory attention. The FDA's accelerated approval of zongertinib (Hernexeos) in February 2026 represents a meaningful advance for this molecularly defined subset of lung cancer patients.

Zongertinib is a next-generation, selective, irreversible inhibitor of the HER2 tyrosine kinase. Unlike earlier pan-HER inhibitors, it is engineered to preferentially target HER2 while minimizing off-target effects on EGFR, which has historically been a source of toxicity such as diarrhea and skin rash. The drug is administered orally, which is an important practical consideration for patients managing a chronic, metastatic disease.

The FDA's accelerated approval pathway was used here because the drug demonstrated promising tumor response rates and durable responses in clinical trials, even before overall survival data matured. This pathway allows earlier patient access to potentially transformative therapies while confirmatory trials continue. The approval is specifically limited to non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations, underscoring the importance of molecular testing at diagnosis.

For clinicians, this approval reinforces the critical role of comprehensive genomic profiling in NSCLC workup. Identifying HER2 mutations — distinct from HER2 amplification or overexpression — requires next-generation sequencing, not standard immunohistochemistry. Patients whose tumors harbor these mutations now have a dedicated oral targeted therapy rather than relying solely on chemotherapy or antibody-drug conjugates.

Caveats remain. Accelerated approval is contingent on confirmatory trial results, and long-term survival benefit has not yet been established. The summary here is based on limited publicly available information, and full prescribing data, trial methodology, and safety profiles require direct review of FDA labeling and primary publications.